Stanford grants key IP license to Forty Seven
Stanford University granted its immuno-oncology spin-out Forty Seven Inc. rights to key programs and IP surrounding the development of therapies that stimulate ingestion of cancer cells by the immune system.
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.